

Pharmacogenomic Drug-Gene Interactions in Geriatric Emergency Department

Patients That Have Fallen

Richard D. Shih, MD^{1,2}; Gabriella Engstrom, PhD, RN¹; Abhijit S. Pandya PhD³; Gregg B. Fields PhD⁴; Borivoje Furht PhD³; Ali A. Danesh PhD⁵; Scott M. Alter, MD^{1,2,6}; Humberto Munoz BPharm, CPh, MHSA²; Lisa M. Clayton DO^{1,2,6}; Joshua J. Solano MD^{1,2,6}; Timothy Buckley MD, MPH^{1,2,6}; Olivia Hung¹; Alexander Farag¹; Mike Wells, MBBCh, PhD¹

¹Florida Atlantic University, Charles E. Schmidt College of Medicine

²Department of Emergency Medicine, Delray Medical Center

³Florida Atlantic University, College of Engineering and Computer Science

⁴Florida Atlantic University, Charles E. Schmidt College of Science

⁵Florida Atlantic University, College of Education

⁶Department of Emergency Medicine, Bethesda Hospital East

Corresponding Author:

Richard Shih, MD

Florida Atlantic University

Charles E. Schmidt College of Medicine

777 Glades Rd. Bldg. 71

Boca Raton, FL 33431

rshih@health.fau.edu

Declaration of Sources of Funding: This study was supported by a grant from the Florida Medical Malpractice Joint Underwriting Association Grant for Safety of Health Care Services Grant RFA #2022-01. "The Geriatric Emergency Department Fall Injury Prevention (The GREAT FALL)." Principal Investigator: Richard D. Shih MD. The funding sources had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and the decision to submit the manuscript for publication.

Keywords: Geriatrics, Geriatric Emergency Department, Falls, Pharmacogenomic, Polypharmacy

Key Points:

- Polypharmacy is associated with adverse drug events and fall-related injuries.
- Pharmacogenomic can identify drug-gene interactions in older ED adults that sustain a fall.
- Significant drug-gene interactions are common in older ED adults that sustain a fall.
- Pharmacogenomic-guided medication prescribing which may decrease ADEs and improve clinical outcomes

Abstract:

Background: Pharmacogenomic assisted prescribing of medications utilizes individual genetic information to identify drug-gene interactions. We aimed to assess potential pharmacogenomic drug-gene interactions in geriatric emergency department (ED) patients that have sustained a fall.

Methods: This was a prospective study involving 25 older adult ED patients with fall related injury. Data collected included current medications, demographics and mechanism of injury. All patients provided a DNA sample for pharmacogenomic testing, MatchMyMeds (DNA Labs, Boca Raton, FL) which assessed genetic data for 23 enzyme systems and reports on potential drug-gene interactions for 134 medications. Each patients' medications were reviewed against their pharmacogenomic report and categorized as Green (go), Yellow (caution) or Red (stop) based on their genetic information and published interactions by the Clinical Pharmacogenetics Implementation Consortium (CPIC), Dutch Pharmacogenetics Working Group (DPWG) and Food and Drug Administration-approved drug label information. The main study outcome was pharmacogenomic drug-gene interactions.

Results: Of the 25 patients enrolled (median age, 81 years, IQR: 76-85), 68% were female. Patients were taking a median of 8 medications (IQR: 5-11). The most common types were antihypertensives, statins, anticoagulants, and anti-platelet medications. Significant drug-gene interactions (Yellow or Red) were identified in 14/25 (56%) patients. Further, 6/25 (24%) had one or more potentially serious (Red) interactions identified.

Conclusions: In geriatric ED patients with a fall-related injury, a majority have a significant pharmacogenomic drug-gene interactions. DNA testing identifies these interactions and can assist with pharmacogenomic-guided medication prescribing which may decrease ADEs and improve clinical outcomes.

Introduction:

As individuals age, they have more medical problems and are prescribed more medications. Taking more than five medications, i.e., polypharmacy, leads to increased adverse drug events (ADEs), hospitalizations and poor outcomes [1-4]. Of these poor outcomes, falling and fall-related injury are among the most important [1,5].

Stopping a medication, i.e., deprescribing, is a very difficult process [6]. Although several methods for medication assessment and possible discontinuation have been published, most have not been widely adopted and there are many challenges associated with stopping medications [7-11]. Pharmacogenomic tests may provide an objective method for physicians to identify medications that are high risk for ADE and allow them to deprescribe or prescribe medications more precisely and appropriately. The objective of this study was to assess pharmacogenomic drug-gene interactions in geriatric ED patients that have fallen. This may provide the basis for pharmacogenomic-guided medication prescribing in older patients at risk for fall related injury.

Methods:

Study Design and Setting:

We conducted a prospective study involving 25 patients presenting to a single ED with an annual patient volume of 50,000. The study was approved by the hospital's affiliated university institutional review board.

Selection of Participants:

A convenience sample of ED patients aged 65 years or older who had sustained a fall related injury were eligible and consented for participation. We excluded patients with penetrating injuries, injury more than 24 hours prior to presentation and transfer from another hospital. Additionally, we excluded any patients that were hospice and/or Do Not Resuscitate (DNR) status.

Data Collection:

Identified patients who met the study's inclusion and exclusion criteria were approached to complete an IRB-approved informed consent form for study participation. Data were collected by trained research assistants (RAs), who were present in the ED. Data collected included current medications (prescribed pre-injury), demographic data, mechanism of injury, past medical history, and ED diagnosis.

In addition, all patients provided a DNA sample obtained via a single cheek swab sample from the inside of the patient's mouth. The subjects were not allowed to eat, drink, or smoke for 30 minutes prior to swabbing. The pharmacogenomic test utilized was MatchMyMeds (DNA Labs, Boca Raton, FL, <https://dnalabs.ca>). This test analyzes for 23 different metabolic enzyme systems and reviews potential drug-gene interactions for 134 different medications (see Table 1). The MatchMyMeds report is based on the Clinical Pharmacogenetics Implementation Consortium (CPIC, <https://cpicpgx.org>) [12], the Dutch Pharmacogenetics Working Group (DPWG, <https://www.pharmgkb.org/page/dpwg>) [13,14], and Food and Drug Administration-approved drug label information to provide detailed drug and dosing recommendations. In addition, based on the individual's genetics, the report categorized 134 medications as Green (go: use label recommended dosage and administration), Yellow (caution: use with caution - read detailed recommendations for potential dose adjustment) or Red (stop: select alternative treatment if possible - read detailed recommendation for detail).

Outcomes:

The main study outcome was to identify pharmacogenomic drug-gene Interactions. Yellow and Red medications were defined as serious interactions.

A secondary outcome was to assess whether a medication with a significant gene-drug interaction was also identified on the Beers potentially inappropriate medications list [15].

Analysis:

Descriptive analyses were conducted to assess the prevalence and severity of drug-gene interactions, as well as to identify the specific drugs affected. The frequency of interactions within each risk category (Green, Yellow, and Red) was quantified, and the severity of these interactions was characterized based on their potential impact on patient safety and treatment efficacy.

Results:

Twenty-five patients were enrolled. The median age was 81 years (IQR: 76-85) and 68% were female. The most frequent co-morbidities were hypertension (64%), atrial fibrillation (32%), coronary artery disease (28%) and stroke (8%).

All patients were on medications for pre-existing co-morbidities (see Table 2). Patients were taking a median of 8 medications (IQR: 5-11). The most common types were antihypertensives, statins, anticoagulants, and anti-platelet medications. All the patients had suffered a fall, as this was part of the inclusion criteria. Most had contusions, fractures and wounds. Several also had significant medical problems such as stroke, head injury and syncope (see Table 3).

When considering the pharmacogenomic data and drug-gene interactions, of our 25 patients, 14/25 (56%) had one or more Yellow or Red medications (see figure 1) for a total of 20 significant gene-drug interactions (see Table 4). Further, 6/25 (24%) had one or more Red medications identified (see Figure 1). The implicated medications were those that could increase risk of falling with several drugs with the potential for increased sedation (escitalopram, tramadol, trazodone, oxycodone and duloxetine) and others potentially causing bradycardia or hypotension (metoprolol and amlodipine).

Discussion:

As an individual gets older, they develop more medical problems and are prescribed more medicines. The more medications that someone takes, the higher the risk for an ADE [16]. Polypharmacy, taking five or more medicines is a major risk factor for an ADE [17].

Shaver et. al. in 2021 showed that mortality risk in older United States (US) persons from falls increased steadily from 1999 to 2017, as the use of Fall Risk Increasing Drugs (FRIDs) increased. During that period, the percentage of older people taking a FRIDs increased from 57% to 97% [3].

On average, 750 US older adults are hospitalized each day due to an ADE and 50% are taking seven or more medications [5,11]. Further, about 60% of older people have one or more medicines that are unnecessary [18]. Among geriatric ED patients about 75% have one or more medications that are classified as “avoid” or “use with caution [6].”

However, stopping a medication (deprescribing) has proven to be very difficult for patients and physicians [11]. Although a number of methods for medication assessment and possible discontinuation have been published, most have not been widely adopted [7-9,15,19]. Deprescribing presents several significant challenges in clinical practice including doctors lacking training in stopping medications, doctors worrying about worsening symptoms, patients worrying about worsening symptoms, concern for withdrawal, the time required to discuss medication changes, and patients feeling like their doctor is “giving up” and no longer treating their disease [11,12,20].

Pharmacogenomics may provide an objective means to help with this problem. It is a genetic means to assess for possible risk of ADEs and may one day become standard information for physicians to help provide more precise and personalized prescribing of medications. Pharmacogenomics involves gene testing to assess how an individual metabolizes medications. Hepatic enzymes in the P450 systems (i.e. CYP2D6, CYP3A4, CYP2C19) are responsible for metabolizing many commonly used medications (i.e. Lipitor®, Valium®, warfarin, Xarelto®, Zolof®t®, and many others). In addition, CYP2D6 has many different genetic polymorphisms and depending on the inherited alleles the individual CYP2D6 system may function as poor, intermediate, extensive or ultrarapid metabolizers [21].

Most people are intermediate and extensive metabolizers and in our current system of dosing medications, a “one size fits all” approach, the standard dose will provide concentrations in the therapeutic

window predictably. However, if they are a poor metabolizer or ultrarapid metabolizer, a given medication may be in the toxic or ineffective concentration range.

In our study each patient's medications was assessed for a potential for a drug-gene interaction based on DNA Labs pharmacogenomic report. Of our 25 patients, there were a total of 20 (Red or Yellow) significant potential drug-gene interactions identified with 56% having one or more Yellow or Red medications (see Figure and 5). In addition, 20% had at least one red drug-gene medication interaction identified. Examples of significant gene-drug interactions include:

- Reduced CYP2D6 enzyme activity in someone taking metoprolol. These individuals are poor metabolizers of metoprolol and have a three-to-ten-fold higher concentration compared to an extensive metabolizer. Further, poor metabolizers had a five times higher rate of ADE compared to non-poor metabolizers. These ADE include symptomatic bradycardia and dizziness [22].
- Reduced CYP2C19 enzyme activity in someone taking clopidogrel. Approximately 30% of individuals taking clopidogrel have reduced or zero CYP2C19 activity which leads to decreased platelet inhibition effect and worse cardiovascular outcomes [23].

An additional important finding is that many of the gene-drug interactions that were identified are not on the American Geriatrics Society 2023 updated AGS Beers Criteria® (see Table 4) [15]. The medication involved in 11 of the 20 (55%) significant potential drug-gene interactions are not on this Beers list. The Beers Criteria® is a list of potentially inappropriate medications for older adults. It is developed by a panel of interprofessional experts who review the published literature to establish this list. This list does not appear to reflect potential drug-gene medication interactions, as more than 50% of the medicines involved in interactions identified in our study were not on the Beers list.

Limitations:

This study was a small convenience sample of 25 patients without a comparison group. A larger study with more participants would give a more precise percentage of gene-drug interactions and identify more infrequently occurring ones.

A second limitation is that the gene-drug interactions identified are potential ones and ADEs were not examined as part of this study. A randomized controlled trial utilizing the pharmacogenomic assisted prescribing of medications would be the ideal method to assess for ADEs and the clinical impact of the significant gene-drug interactions that were identified.

A third limitation is that even if individual pharmacogenomic data were available, it is not clear if physicians would utilize this for improved prescribing. One of the barriers is the difficulty in interpreting the pharmacogenomic data leading to an increased amount of time and lack of user-friendly guideline information [12,20,24]. This study did not assess this and is another future area of research for the implementation of pharmacogenomic assisted prescribing practices.

Conclusions:

In geriatric ED patients that present for a fall-related injury, a majority have a significant pharmacogenomic drug-gene interactions. DNA testing can identify these interactions and can assist with pharmacogenomic-guided medication prescribing, which has the potential to decrease ADEs and improve clinical outcomes.

References

1. Xing XX, Zhu C, Liang HY *et al.* Associations between potentially inappropriate medications and adverse health outcomes in the elderly: A systematic review and meta-analysis. *Ann Pharmacother* 2019; 53: 1005-19.
2. Budnitz DS, Shehab N, Lovegrove MC *et al.* US emergency department visits attributed to medication harms, 2017-9. *JAMA* 2021; 326: 1299-309.
3. Shaver AL, Clark CM, Hejna M *et al.* Trends in fall-related mortality and fall risk increasing drugs among older individuals in the United States, 1999-2017. *Pharmacoepidemiol Drug Saf* 2021;30: 1049-1056.
4. Koehl JL. Adverse Drug Event Prevention and Detection in Older Emergency Department Patients. *Clin Geriatr Med* 2023; 39: 635-45.
5. Flaherty JH, Perry HM 3rd, Lynchard GS *et al.* Polypharmacy and hospitalization among older home care patients. *J Gerontol A Biol Sci Med Sci* 2000; 55: 554-9.
6. Harrison L, O'Connor E, Jie C *et al.* Potentially inappropriate medication prescribing in the elderly: is the beers criteria relevant to the emergency department today? *Am J Emerg Med* 2019; 37: 1734-7.
7. O'Mahony D, O'Sullivan D, Byrne S *et al.* STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing* 2015; 44: 213-8.
8. Boyé ND, van der Velde N, de Vries OJ *et al.* Effectiveness of medication withdrawal in older fallers: results from the improving medication prescribing to reduce risk of falls (IMPROveFALL) trial. *Age Ageing* 2017; 46: 142-6.
9. Stevens M, Hastings SN, Markland AD *et al.* Enhancing quality of provider practices for older adults in the emergency department (EQUIPPED). *J Am Geriatr Soc* 2017; 65: 1609-14.
10. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS beers criteria for potentially inappropriate medication use in older adults. *J Am Geriatr Soc* 2019; 67: 674-694.
11. Rubin R. Deciding When It's Better to Deprescribe Medicines Than to Continue Them. *JAMA* 2023; 330: 2328-30.
12. Relling MV, Klein TE, Gammal RS *et al.* The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. *Clin Pharmacol Ther* 2020; 107: 171-5.
13. Bank PCD, Caudle KE, Swen JJ *et al.* Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. *Clin Pharmacol Ther* 2018; 103: 599-618.
14. Caudle KE, Sangkuhl K, Whirl-Carrillo M *et al.* Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. *Clin Transl Sci* 2020 Jan;13(1):116-124.
15. 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. *J Am Geriatr Soc* 2023; 71: 2052-81.
16. Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. *Clin Geriatr Med* 2012; 28: 173-86.
17. Masnoon N, Shakib S, Kalisch-Ellett L *et al.* What is polypharmacy? A systematic review of definitions. *BMC Geriatr* 2017; 17: 230. doi: 10.1186/s12877-017-0621-2.
18. Schmader KE, Hanlon JT, Pieper CF *et al.* Effects of geriatric evaluation and management on adverse reactions and suboptimal prescribing in the frail elderly. *Am J Med* 2004; 116: 394-401.
19. Shih RD, Carpenter CR, Tolia V *et al.* Balancing vision with pragmatism: The geriatric emergency department guidelines- realistic expectations from emergency medicine and geriatric medicine. *J Am Geriatr Soc* 2022; 70: 1368-73.
20. Relling MV, Klein TE. Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. *Clin Pharmacol Ther* 2011; 89: 464-7.
21. Crews KR, Gaedigk A, Dunnenberger HM *et al.* Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. *Clin Pharmacol Ther* 2014; 95: 376-82.
22. Wuttke H, Rau T, Heide R *et al.* Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. *Clin Pharmacol Ther* 2002; 72: 429-37.
23. Thomas CD, Williams AK, Lee CR *et al.* Pharmacogenetics of P2Y12 receptor inhibitors. *Pharmacotherapy* 2023; 43: 158-175.

24. Roth M, King L, St Cyr K *et al.* Evaluating the prospective utility of pharmacogenetics reporting among Canadian Armed Forces personnel receiving pharmacotherapy: a preliminary assessment towards precision psychiatric care. *BMJ Mil Health* 2023 Sep 1:e002447. doi: 10.1136/military-2023-002447. Online ahead of print.

Table 1. Metabolic Enzyme System Genes Analyzed and Medications Assessed for Drug-Gene Interactions

Gene Symbol	Gene Name
ABCB1	ATP binding cassette subfamily B member 1 (ABCB1) gene
APOE	Apolipoprotein E (APOE) gene
COMT	Catechol-O-methyl-transferase (COMT) gene
CYP1A2	Cytochrome P450 1A2 (CYP1A2), mixed-function oxidase system gene
CYP2B6	Cytochrome P450 2B6 (CYP2B6), mixed-function oxidase system gene
CYP2C19	Cytochrome P450 2C19 (CYP2C19), mixed-function oxidase system gene
CYP2C9	Cytochrome P450 2C9 (CYP2C9), mixed-function oxidase system gene
CYP2D6	Cytochrome P450 2D6 (CYP2D6), mixed-function oxidase system gene
CYP3A4	Cytochrome P450 3A4 (CYP3A4), mixed-function oxidase system gene
CYP3A5	Cytochrome P450 3A5 (CYP3A5), mixed-function oxidase system gene
DPYD	Dihydropyrimidine dehydrogenase (DPYD) gene
DRD2	Dopamine D2 receptor (DRD2) gene
F2	Coagulation factor II (F2) gene
F5	Coagulation factor V (F5) gene
GLP1R	Glucagon-like peptide 1 (GLP1R) gene
MTHFR	Methylenetetrahydrofolate reductase (MTHFR) gene
NUDT15	Nudix hydrolase 15 (NUDT15) gene
OPRM1	Opioid receptor mu 1 (OPRM1) gene
PNPLA5	Patatin like phospholipase domain containing 5 (PNPLA5) gene
SLCO1B1	Solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene
SULT4A1	Sulfotransferase Family 4A Member 1 (SULT4A1) gene
TPMT	Thiopurine S-methyltransferase (TPMT) gene
VKORC1	Vitamin K epoxide reductase complex subunit 1 (VKORC1) gene
Class	Drugs
Anti-Anxiety/Anti-Depression	amitriptyline (Elavil), amoxapine (Asendin), bupropion (Wellbutrin), citalopram (Celexa), clomipramine (Anafranil), desipramine (Desipramine), doxepin (Sinequan, Silenor), duloxetine (Cymbalta), escitalopram (Cipralext), fluvoxamine (Luvox), imipramine (Impril), levomilnacipran (Fetzima), mirtazapine (Remeron), nortriptyline (Aventyl), paroxetine (Paxil), protriptyline (Vivactil), sertraline (Zoloft), trazodone (Oleptro), trimipramine (Trimipramine), venlafaxine (Effexor), vilazodone (Viibryd), vortioxetine (Trintellix), diazepam (Valium)
Birth Control	hormonal contraceptives for systemic use
Cardiovascular	acenocoumarol (Sintrom), amlodipine (Norvasc), apixaban (Eliquis), atorvastatin (Lipitor), clopidogrel (Plavix), cilostazol (Pletal), dronedarone (Multaq), flecainide (Tambocor), metoprolol (Lopresor, Betaloc), phenprocoumon, propafenone (Propafenone), simvastatin (Zocor), warfarin (Coumadin), fluvastatin (Lescol, Fluvastatin), lovastatin (Advicor, Mevacor), pitavastatin (Livalo, Zypitamag), pravastatin (Pravachol), rosuvastatin (Crestor), ranolazine (Ranexa), rivaroxaban (Xarelto)
Dentistry	cevimeline (Evoxac)
Dermatology	abrocitinib (Cibinqo)
Endocrinology	eliglustat (Cerdelga)
Gastroenterology	aprepitant (Emend), dexlansoprazole (Dexilant), dronabinol (Marinol), esomeprazole (Nexium), lansoprazole (Prevacid), metoclopramide (Reglan), omeprazole (Losec), ondansetron (Zofran), pantoprazole (Pantoloc), tropisetron (Navoban), rabeprazole (Aciphex)
Immunology	azathioprine (Imuran), dexamethasone (Dexamethasone), tacrolimus (Prograf)
Infectious Diseases	efavirenz (Sustiva), voriconazole (Vfend)
Neurology	donepezil (Aricept), eszopiclone (Lunesta), fosphenytoin (Cerebyx, Sesquient), phenytoin (Dilantin), clobazam (Frisium), siponimod (Mayzent), tetrabenazine (Nitoman), brivaracetam (Brivlera, Briviact), deutetrabenazine (Austedo), dextromethorphan and Quinidine (Nuedexta), valbenazine (Ingrezza), lacosamide (Vimpat), pitolisant (Wakix), Zopiclone (Imovane)

Oncology	mercaptopurine (Purinethol), 5-fluorouracil (Aduvicol), capecitabine (Xeloda), tamoxifen (Nolvadex), thioguanine (Lanvis), cabazitaxel (Jevtana), cisplatin (Platinol), tegafur (Teysuno)
Pain	almotriptan (Axert), buprenorphine and naloxone (Suboxone), codeine, fentanyl (Duragesic), eletriptan (Relpax), ibuprofen (Advil, Motrin), oxycodone, celecoxib (Celebrex), hydrocodone, lornoxicam (Chlortenoxicam), tenoxicam (Tenoxicam), piroxicam, tramadol (Tridural, Tramacet), zolmitriptan (Zomig)
Psychiatry	aripiprazole (Abilify), atomoxetine (Strattera), brexpiprazole (Rexulti), clozapine (Clozaril), guanfacine (Intuniv, Tenex), haloperidol (Haloperidol), lurasidone (Latuda), perphenazine, pimozide (Orap), pimavanserin (Nuplazid), risperidone (Risperdal), thioridazine (Mellaril), zuclopenthixol (Clopixol), amphetamine (Adderall, Adzenys), iloperidone (Fanapt), lisdexamfetamine (Vyvanse), quetiapine (Seroquel)
Pulmonology	fluticasone furoate and vilanterol (Breo Ellipta), fluticasone, umeclidinium, and vilanterol (Trelegy Ellipta), umeclidinium and vilanterol (Anoro Ellipta)
Rheumatology	carisoprodol (Soma), flurbiprofen, lesinurad (Zurampic), meloxicam (Mobic)
Urology	tamsulosin (Flomax), dapoxetine (Priligy), fesoterodine (Toviaz), tolterodine (Detrol), darifenacin (Enablex), sildenafil (Viagra), tadalafil (Cialis)

Table 2: Clinical Characteristics

Patients	
N=25	
Past Medical History, n (%)	
Hypertension	16 (64)
Atrial fibrillation	8 (32)
Coronary artery disease	7 (28)
Solid tumor/Cancer active	4 (16)
Cerebrovascular attack	2 (8)
Valve replacement	2 (8)
Myocardial infarction	2 (8)
Diabetes	1 (4)
Chronic obstructive pulmonary disease	1 (4)
Congestive heart failure	1 (4)
Pulmonary embolism	1 (4)
Peripheral vascular disease/peripheral stent	1 (4)
Chronic kidney disease	1 (4)

Table 3: Patients' Emergency Department Diagnosis

Patient	Emergency Department Diagnosis
1	Fall, head injury, nasal fracture, laceration of right hand, laceration of left index finger.
2	Fall, head injury, scalp contusion
3	Fall, fracture of lumbar vertebrae
4	Fall, head injury, right rib fracture, knee contusion, scalp laceration.
5	Fall, repeated falls, syncope, hypokalemia, head injury, neck injury
6	Fall, fractures of right and left wrist
7	Fall, head injury, scalp laceration, contusions
8	Fall, hip contusion
9	Fall, head injury, contusions
10	Fall, hip contusion
11	Fall, fracture of wrist
12	Fall, fracture of lumbosacral vertebrae
13	Fall, left rib fracture
14	Fall, fracture of distal left radius
15	Fall, head injury, wrist fracture, atrial fibrillation
16	Fall, head injury, scalp contusion
17	Fall, fracture of right wrist
18	Fall, urinary tract infection, rhabdomyolysis.
19	Fall, head injury, scalp laceration
20	Fall, right rib fracture and right shoulder contusion
21	Fall, head injury, scalp laceration
22	Fall, fracture of femur
23	Fall, fracture of femur and fracture of clavicle
24	Fall, head injury, forehead laceration and cerebral infarction
25	Fall, head injury, contusions and viral syndrome

Table 4: Significant Drug-Gene Interactions

Pt	Drug	Enzyme System Involved	Possible Outcome and clinical significance	AGS Beers list ¹⁵
4	Escitalopram	Reduced CYP2C19 activity	Level increased	No
	Metoprolol	Reduced CYP2D6 activity	Level increased – hypotension, bradycardia	No
	Clopidogrel	Reduced CYP2C19 activity	Level decreased – increased risk of thrombosis	No
5	Pantoprazole	Reduced CYP2C19 activity	Level increased	Yes
6	Tramadol	Elevated CYP2D6 activity	Level of metabolite (increased morphine)	Yes
9	Paroxetine	Reduced CYP2D6 activity	Level increased	Yes
12	Warfarin	CYP2C9 and VKORC1 variants	Variable effect on level	Yes
	Metoprolol	Reduced CYP2D6 activity	Level increased – hypotension, bradycardia	No
13	Escitalopram	Reduced CYP2C19 activity	Level increased	No
	Clopidogrel	Reduced CYP2C19 activity	Level decreased – increased risk of thrombosis	No
14	Pantoprazole	Reduced CYP2C19 activity	Level increased	Yes
17	Trazodone	Reduced CYP3A4 activity	Level increased	No
19	Metoprolol	Reduced CYP2D6 activity	Level increased – hypotension, bradycardia	No
20	Celecoxib	Reduced CYP2C9 activity	Level increased	Yes
	Oxycodone	Reduced CYP2D6 activity	Level increased – toxic opioid effect	Yes
21	Duloxetine	Reduced CYP2D6 and Elevated CYP1A2 activity	Level increased	Yes
23	Pantoprazole	Elevated CYP2C19 activity	Level decreased	Yes
	Escitalopram	Elevated CYP2C19 activity	Level decreased	No
24	Amlodipine	Reduced CYP3A4 activity	Level increased – hypotension	No
	Apixaban	Reduced CYP3A4 activity	Level increased – increased bleeding	No

Figure 1.




Figure: Possible drug-gene medication interactions for each patient